Charles River Laboratories International, Inc. (NYSE:CRL) Stock Position Reduced by Compass Wealth Management LLC

Compass Wealth Management LLC lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 66.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 233 shares of the medical research company’s stock after selling 466 shares during the quarter. Compass Wealth Management LLC’s holdings in Charles River Laboratories International were worth $43,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its stake in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Wolff Wiese Magana LLC acquired a new position in Charles River Laboratories International in the third quarter worth approximately $32,000. Pinnacle Bancorp Inc. raised its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares in the last quarter. Assetmark Inc. lifted its stake in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 173 shares during the last quarter. Finally, ORG Wealth Partners LLC bought a new stake in Charles River Laboratories International in the fourth quarter worth approximately $56,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

CRL has been the topic of a number of recent research reports. UBS Group restated a “neutral” rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. The Goldman Sachs Group cut their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday. TD Cowen upped their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Bank of America cut their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Finally, CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research report on Monday, November 18th. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $204.38.

Insider Transactions at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $164.88 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The company has a market cap of $8.43 billion, a PE ratio of 20.64, a price-to-earnings-growth ratio of 5.94 and a beta of 1.38. The firm has a fifty day moving average price of $186.75 and a two-hundred day moving average price of $197.24. Charles River Laboratories International, Inc. has a fifty-two week low of $160.85 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same period last year, the business earned $2.72 earnings per share. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. Analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).